- Home
- DSP vs NBP Comparison
DSP vs NBP Comparison
Compare DSP & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSP | NBP |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 225.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DSP | NBP |
|---|---|---|
| Price | $11.43 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $17.81 | $9.00 |
| AVG Volume (30 Days) | 237.0K | ★ 770.0K |
| Earning Date | 05-11-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,201,000.00 | N/A |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $16.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.11 | $1.46 |
| 52 Week High | $15.18 | $5.19 |
Technical Indicators
Market Signals| Indicator | DSP | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 47.57 |
| Support Level | $10.77 | $1.67 |
| Resistance Level | $12.61 | $1.95 |
| Average True Range (ATR) | 0.77 | 0.17 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 4.57 | 17.25 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.